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Abstract
Background:  Although percutaneous coronary intervention (PCI) is becoming the standard
therapy in ST-segment elevation myocardial infarction (STEMI), to date most patients, even in
developed countries, are reperfused with intravenous thrombolysis or do not receive a reperfusion
therapy at all. In the post-lysis period these patients are at high risk for recurrent ischemic events.
Early identification of these patients is mandatory as this subgroup could possibly benefit from an
angioplasty of the infarct-related artery.
Since viability seems to be related to ischemic adverse events, we initiated a clinical trial to
investigate the benefits of PCI with stenting of the infarct-related artery in patients with viability
detected early after acute myocardial infarction.
Methods: The VIAMI-study is designed as a prospective, multicenter, randomized, controlled
clinical trial. Patients who are hospitalized with an acute myocardial infarction and who did not have
primary or rescue PCI, undergo viability testing by low-dose dobutamine echocardiography
(LDDE) within 3 days of admission. Consequently, patients with demonstrated viability are
randomized to an invasive or conservative strategy. In the invasive strategy patients undergo
coronary angiography with the intention to perform PCI with stenting of the infarct-related
coronary artery and concomitant use of abciximab. In the conservative group an ischemia-guided
approach is adopted (standard optimal care).
The primary end point is the composite of death from any cause, reinfarction and unstable angina
during a follow-up period of three years.
Conclusion: The primary objective of the VIAMI-trial is to demonstrate that angioplasty of the
infarct-related coronary artery with stenting and concomitant use of abciximab results in a clinically
important risk reduction of future cardiac events in patients with viability in the infarct-area,
detected early after myocardial infarction.
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Background
Management of acute myocardial infarction (AMI) has
underwent considerable changes in the last two decades
and the management of patients with AMI has become
more established [1,2]. In patients with ST-segment eleva-
tion myocardial infarction (STEMI), primary angioplasty
is becoming first-choice therapy [2-4]. However, because
of the low availability of such treatment, even in devel-
oped countries, most patients with STEMI are reperfused
with intravenous thrombolysis. Many patients do not
receive a reperfusion therapy at all [5,6].
Data from large clinical trials indicate that after successful
thrombolysis more than 50% of patients have a signifi-
cant residual stenosis and about 30% of patients have
spontaneous or inducible ischemia [7-9]. In this group
reocclusion of the infarct-related artery is a potential
threat, as it is associated with recurrent ischemia or recur-
rent infarction [10,11]. Therefore, early risk assessment is
of great importance, especially in patients treated with
thrombolysis and patients who did not receive reper-
fusion therapy. This risk assessment should be followed
by an effective treatment strategy in order to prevent recur-
rent cardiac events and deterioration of left ventricular
function [12,13]. As these recurrent events are mainly due
to the presence of an unstable residual stenosis of the inf-
arct-related coronary artery, an effective therapy should
include an invasive procedure like angioplasty to opti-
mize coronary flow to the infarct area in high risk patients
[11].
Trials have been performed to study the effect of routine
angioplasty on clinical outcome early after AMI treated
with thrombolysis [14-20]. Most of these studies failed to
show improvement of clinical outcome with a standard
invasive approach. Possible explanations for these results
are the unselected approach, and the high risk profile of
balloon angioplasty in the early days, when abciximab
and stents were not available. Because angioplasty always
carries an inherent risk, it remains important to select
those patients after a recent myocardial infarction, who
will actually benefit from angioplasty of the infarct-related
artery.
To date, non-invasive risk stratification after AMI has
mainly focused on exercise stress testing. The inability to
exercise, the low diagnostic accuracy and resting ECG
abnormalities, however, remain important limitations in
the detection of ischemia [21].
Several post-infarction observational studies investigated
viability as prognosticator and showed that the presence
of viability in the infarct area was highly predictive for
future coronary events like recurrent ischemia, recurrent
infarction, left ventricular failure, and death [22-31]. Via-
ble tissue is potentially jeopardized by an unstable resid-
ual stenosis in the infarct-related coronary artery. In a
meta-analysis of non-randomized data by Iskandrian, the
impact of revascularization on clinical outcome in
patients with viability after AMI was studied [32]. A signif-
icant decrease in future cardiac events was observed in the
patients with viability who were revascularized. In con-
trast, the outcome in patients without viability in the inf-
arct area did not change by an invasive strategy.
In this context it should be noted that other post-infarc-
tion studies have shown viability to be associated with an
improved prognosis [33-36]. Two studies demonstrated
that especially patients with severe LV dysfunction and
viability show a better survival than patients with LV dys-
function but without viability [34,36]. The reason for this
paradox is not quite understood. However, it can be
argued that patients with viability have a potential of
recovery of LV function (spontaneous or by revasculariza-
tion), thereby improving their survival [37]. Thus, on one
hand viability may improve survival by recovery of func-
tion especially in patients with moderate to severe LV dys-
function, on the other hand viability is related to a worse
prognosis by increased risk of recurrent ischemic events.
Based on the aforementioned assumptions, we initiated a
clinical trial to investigate the benefits of percutaneous
coronary intervention (PCI) of the infarct-related artery in
patients with viability detected in the early, subacute
phase of myocardial infarction. To demonstrate viability,
we use low-dose dobutamine echocardiography (LDDE).
This test can safely be performed 48 hours after acute MI
[23,27,30,31]. It is a well validated bedside test with a
diagnostic accuracy of about 80%, which is comparable to
scintigraphical techniques (SPECT/PET) [38]. Coronary
stenting will be performed with concomitant use of abcix-
imab. After stenting, oral clopidogrel is given in a stand-
ard way. With this approach the lowest possible
periprocedural event rate will be attained, with a low rate
of target vessel revascularization (TVR) [39-43].
We hypothesize that, in order to prevent future cardiac
events, PCI is only useful in patients with viability in the
infarct zone early after myocardial infarction.
Methods
Patient Selection
Patients admitted to any of the participating centers with
an acute or recent myocardial infarction, who are not
treated by direct or rescue angioplasty, and who are stable
during the first 48 hours after the acute event, are screened
for the study. Patients < 80 years of age are considered
suitable for the study when they have definite myocardial
infarction, as demonstrated by an significant rise in creat-
ine kinase-MB levels (twice the upper limit of normal:Current Controlled Trials in Cardiovascular Medicine 2004, 5:11 http://cvm.controlled-trials.com/content/5/1/11
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ULN), 1 mm ST segment elevation in two or more stand-
ard leads or 2 mm ST segment elevation in two contiguous
chest leads, and/or the development of Q waves.
The criteria for exclusion are: viability testing technically
not possible (poor echo-window), contraindications for
dobutamine echocardiography (arrhythmia), and coro-
nary angiography (severe diabetic nephropathy or known
contrast-allergy), serious life-threatening non-cardiac ill-
ness, ECG abnormalities making the evaluation of the ST
segment impossible (left bundle branch block, pace-
maker), and an unreliable follow-up.
The study complies with the Declaration of Helsinki and
all ethics committees of the participating centers have
approved the protocol. All eligible patients provide writ-
ten informed consent.
Study design
The study is a prospective, multicenter, randomized, con-
trolled clinical trial. In the VIAMI-trial, patients who are
admitted to the hospital with an acute myocardial infarc-
tion and who did not undergo primary or rescue PCI, are
evaluated by LDDE within 3 days of admission. Patients
with unequivocal signs of viability in the infarct-area are
randomized to an invasive or a conservative treatment
strategy. In the invasive strategy patients undergo coro-
nary angiography with the intention to perform PCI with
stenting of the infarct-related coronary artery. In the con-
servative group an ischemia-guided approach is adopted
with stress testing before discharge from the hospital.
When the test is highly suggestive for ischemia, coronary
angiography will be performed. If revascularization is per-
formed, this will be scored as a secondary endpoint.
Patients without viability will serve as a registry group
with long-term follow-up (Fig 1). These patients are
assigned to the conservative group in order to prevent
physicians' bias during the trial.
The primary endpoint is the composite of death from any
cause, recurrent infarction, and unstable angina. The sec-
ondary endpoints are need for revascularization, the
occurrence of angina pectoris (CCS classification), and the
incidence of heart failure (NYHA classification). Left ven-
tricular function is also evaluated as determined by
echocardiography at 3 months, 6 months, and 1 year
follow-up.
A reinfarction is diagnosed if there is an increase in the
total creatine kinase and MB isoenzyme activity (2 times
ULN) and either a history of ischemic chest discomfort, or
electrocardiographic changes indicative for transmural
ischemia or necrosis.
For the diagnosis of unstable angina, the patient must be
hospitalized with ischemic chest pain or discomfort
occurring at rest or with minimal exertion. In addition,
the need for intravenous medical intervention and/or
objective evidence of myocardial ischemia is required. For
extensive description of the end points definitions, see
Table 1.
A clinical endpoints and safety monitoring committee
will continuously check and monitor all events in a
blinded manner. Reinfarction after revascularization will
be scored as described in Table 1. Major and minor bleed-
ing complication in the invasive treated group are defined
according to the criteria of the Thrombolysis in Myocar-
dial Infarction trials [44]. All patients will be treated with
aspirine, beta blockers, angiotensin-converting-enzyme
inhibitors and statins as accepted in international guide-
lines [2,4].
Low-dose dobutamine echocardiography
If the inclusion criteria are met and none of the criteria for
exclusion, viability testing by LDDE is performed within 3
days of admission.
Preferably, beta-blockers are withdrawn 24 hours before
the test [23,27,30,31]. Discontinuation of beta-blockers
seems to to enhance LDDE accuracy [45,46]. Before the
administration of dobutamine, a baseline echocardio-
gram is obtained according to the guidelines of the Amer-
ican Society of Echocardiography [47]. Five standard
views are obtained: the parasternal long-axis and short-
axis view and the apical two, three- and four-chamber
view. A 16-segment model is used in which the apex is
divided in 4 segments. Segmental wall motion and thick-
ening is scored according to a 4-point scale: 1 = normal, 2
= hypokinetic, 3 = akinetic, and 4 = dyskinetic. Left ven-
tricular volumes and ejection fraction are measured by use
of the modified Simpson's rule algorithm from orthogo-
nal apical long-axis projections as recommended by the
American Society of Echocardiography.
Dobutamine is administrated intravenously at doses of 5,
10, and 15 µg/kg/min, for 5 minutes at each dose. When
a 10% increase in heart rate is not achieved with 15 µg/kg/
min, a 5-minute infusion with 20 µg/kg/min can be used
as the final stage of the procedure.
Viability is defined as the improvement of wall motion
abnormalities in two or more segments of the infarct
zone. Changes from hypokinesia to normokinesia and
from dyskinesia or akinesia to hypo- or normokinesia are
considered an improvement in wall motion abnormality.
Dyskinesia changing to akinesia is not considered as an
improvement. Patients are continuously monitored by a
12 lead ECG and blood pressure is recorded at the end ofCurrent Controlled Trials in Cardiovascular Medicine 2004, 5:11 http://cvm.controlled-trials.com/content/5/1/11
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Flow chart Figure 1
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each stage. All views are recorded at rest and during dob-
utamine on VHS videotape. All videotapes are sent to the
core-lab (VU University medical center) and will be ana-
lyzed by 2 experienced observers. A third observer is used
in case of disagreement to reach consensus.
For subsequent off-line analysis, the echocardiographic
images will be digitized from VHS videotape and trans-
ferred to a working station (Enconcert® by Philips). The
images will be displayed side-by-side in a quadscreen for-
mat to facilitate the comparison of images.
Coronary angiography and angioplasty
Angiography and angioplasty will be performed as soon
as possible after randomization. Coronary angiography
will be performed according to standard protocols. To
determine the severity of culprit lesions, quantitative cor-
onary arteriography (QCA) will be performed to measure
percent diameter stenosis, reference diameter and cross-
sectional area stenosis. The degree of stenosis will be
determined in the view in which the stenosis is most
severe.
When feasible, PCI will be performed (with or without
etc) when there is a significant (≥ 50%) stenosis or occlu-
sion of the infarct-related coronary artery, with the inten-
tion to perform primary stenting of the infarct-related
artery, with concomitant use of abciximab, according to
the EPILOG protocol [39] After stenting, all patients
recieve oral clopidogrel in a standard way. In case of
severe 3-vessel disease or significant left main stem steno-
sis, where PCI is judged to be a high risk, coronary artery
bypass grafting will be considered.
Follow-up
Patients will be followed for a period of three years. Fol-
low-up data will be obtained of all patients during visits at
the outpatient clinic in the first year, and by telephone
interview in the second and third year of follow-up. Left
ventricular function (volumes and ejection fraction) is
determined by echocardiography at 3 months, 6 months,
and 1 year of follow-up.
Statistical design
The VIAMI-trial is conducted to investigate the differences
in clinical outcome between an invasive and a conserva-
tive strategy in patients with demonstrated viability in the
infarct-area. The expected event rate in the viability posi-
tive group is estimated to be 35 percent. To demonstrate
with a power of 80% (α = 0.05, two-sided) that PCI leads
to a 50% reduction in event rate in the invasive group
compared to the conservative group, 200 patients will be
needed in each group. Therefore, we intend to randomize
a total of 400 patients in this trial, with interim analysis
after 200 included patients.
The formal stopping rules for the study are the following:
If one of the treatment strategies appears significant supe-
rior at interim analysis (P ≤ 0.01), the study will be
stopped.
Table I: Primary end point definitions
Definition of reinfarction
1. Reinfarction during hospitalization for index infarct and not related to revascularization procedures
- Either ischemic type of chest discomfort or new electrocardiographic changes indicative for transmural ischemia or necrosis with an increase in 
the total creatine kinase and MB isoenzyme activity. The activity of CK-MB has to be at least 2 times the upper limit of normal and more than 50% 
above the previous baseline value.
2. Reinfarction discharge for index infarct and not related to revascularization procedures
- Either a history of ischemic chest discomfort, usually lasting > 20 minutes, or classic electrocardiographic changes indicative for transmural 
ischemia with an increase in the total creatine kinase and MB isoenzyme activity of at least 2 times the upper limit of normal.
- New abnormal Q-waves (amplitude ≥ 1/3 of total QRS amplitude and ≥ 0.04 seconds) in ≥ 2 contiguous leads.
3. Periprocedural reinfarction during revascularization after index infarct 
PCI
- Classic electrocardiographic changes indicative for transmural ischemia with an increase in the total creatine kinase and MB isoenzyme activity of 
at least 2 times the upper limit of normal.
- New abnormal Q-waves (amplitude ≥ 1/3 of total QRS amplitude and ≥ 0.04 seconds) in ≥ 2 contiguous leads.
CABG
- Classic electrocardiographic changes indicative for transmural ischemia with an increase in the total creatine kinase and MB isoenzyme activity of 
at least 5 times the upper limit of normal.
- New abnormal Q-waves (amplitude ≥ 1/3 of total QRS amplitude and ≥ 0.04 seconds) in ≥ 2 contiguous leads.
Definition of unstable angina
- Ischemic type of chest discomfort at rest or with minimal exertion, with a duration of at least 15 minutes. The presenting symptoms must 
represent a change from the patients' usual anginal pattern.
- Either a need for intravenous medical intervention and/or objective evidence of myocardial ischemia (dynamic ST changes in ≥ 2 contiguous 
electrocardiographic leads, or an abnormal elevation of Troponin-T or Troponin-I without a significant rise of CK MB isoenzyme activity)
PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; CK-MB, creatine kinase myocardial enzymeCurrent Controlled Trials in Cardiovascular Medicine 2004, 5:11 http://cvm.controlled-trials.com/content/5/1/11
Page 6 of 8
(page number not for citation purposes)
Statistical analysis
Baseline descriptive data will be presented as mean ±
standard deviations (SD). Differences in clinical and
echocardiographic variables will be assessed by unpaired
Student's t test. Differences between proportions will be
assessed by chi-square analysis; a Fisher's exact test will be
used when appropriate. Event-free survival curves are
computed with the Kaplan-Meier method, and the differ-
ences between these curves are tested with a Mantel-Cox
log-rank test. A primary endpoint analysis is planned at 30
days, 6 months, and 1 year of follow-up. Subgroup analy-
ses are planned to determine whether the treatment effect
is more or less pronounced in certain subgroups. The data
will be subgrouped by sex, age, diabetes, anterior infarc-
tion, time from onset of symptoms to treatment, and the
use of thrombolytics. All analyses will be performed on an
intention-to-treat basis. Also, the outcome per-protocol
will be evaluated. Such an analysis seems worthwhile, as
it will reflect the true influence of PCI on post-thrombo-
lytic ischemic events.
Current status
Enrollment of patients started April 1, 2001. Recently, an
interim analysis was performed after the inclusion of 200
patients, having a 30 day follow-up. The Clinical Event
Committee recommended continuation of the trial.
Conclusion
The VIAMI-trial is the first multicenter, randomized, con-
trolled clinical trial, investigating the clinical benefits of
percutaneous catheter intervention of the infarct-related
artery in patients with demonstrated viability in the early,
subacute phase of myocardial infarction.
Competing interests
The authors declare that they have no competing interests.
Authors' contribution
RBvL recruited and analysed all data and drafted the man-
uscript. GV have been involved in drafting the article and
revised it critically. OK and JGFB revised the manuscript
critically. CAV and FCV have given final approval of the
version to be publiced.
References
1. Gunnar RM, Passamani ER, Bourdillon PD, Pitt B, Dixon DW, Rapa-
port E, Fuster V, Reeves TJ, Karp RB, Russell ROJ, .: Guidelines for
the early management of patients with acute myocardial inf-
arction. A report of the American College of Cardiology/
American Heart Association Task Force on Assessment of
Diagnostic and Therapeutic Cardiovascular Procedures
(Subcommittee to Develop Guidelines for the Early Manage-
ment of Patients with Acute Myocardial Infarction). J Am Coll
Cardiol 1990, 16:249-292.
2. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M,
Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ,
Ornato JP, Pearle DL, Sloan MA, Smith SCJ, Alpert JS, Anderson JL,
Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka
LF, Hunt SA, Jacobs AK, Ornato JP: ACC/AHA guidelines for the
management of patients with ST-elevation myocardial inf-
arction; A report of the American College of Cardiology/
American Heart Association Task Force on Practice Guide-
lines (Committee to Revise the 1999 Guidelines for the Man-
agement of patients with acute myocardial infarction). J Am
Coll Cardiol 2004, 44:E1-E211.
3. Keeley EC, Boura JA, Grines CL: Primary angioplasty versus
intravenous thrombolytic therapy for acute myocardial inf-
arction: a quantitative review of 23 randomised trials. Lancet
2003, 361:13-20.
4. Van de WF, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA,
Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Under-
wood SR, Vahanian A, Verheugt FW, Wijns W: Management of
acute myocardial infarction in patients presenting with ST-
segment elevation. The Task Force on the Management of
Acute Myocardial Infarction of the European Society of
Cardiology. Eur Heart J 2003, 24:28-66.
5. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt AK, Boersma E,
Fioretti PM, Simoons ML, Battler A: A prospective survey of the
characteristics, treatments and outcomes of patients with
acute coronary syndromes in Europe and the Mediterranean
basin; the Euro Heart Survey of Acute Coronary Syndromes
(Euro Heart Survey ACS). Eur Heart J 2002, 23:1190-1201.
6. Morrow DA, Antman EM, Parsons L, de Lemos JA, Cannon CP,
Giugliano RP, McCabe CH, Barron HV, Braunwald E: Application of
the TIMI risk score for ST-elevation MI in the National Reg-
istry of Myocardial Infarction 3. JAMA 2001, 286:1356-1359.
7. GISSI-2: a factorial randomised trial of alteplase versus
streptokinase and heparin versus no heparin among 12,490
patients with acute myocardial infarction. Gruppo Italiano
per lo Studio della Sopravvivenza nell'Infarto Miocardico.
Lancet 1990, 336:65-71.
8. ISIS-3: a randomised comparison of streptokinase vs tissue
plasminogen activator vs anistreplase and of aspirin plus
heparin vs aspirin alone among 41,299 cases of suspected
acute myocardial infarction. ISIS-3 (Third International
Study of Infarct Survival) Collaborative Group. Lancet 1992,
339:753-770.
9. The effects of tissue plasminogen activator, streptokinase,
or both on coronary-artery patency, ventricular function,
and survival after acute myocardial infarction. The GUSTO
Angiographic Investigators. N Engl J Med 1993, 329:1615-1622.
10. Meijer A, Verheugt FW, Werter CJ, Lie KI, van der Pol JM, van Eenige
MJ: Aspirin versus coumadin in the prevention of reocclusion
and recurrent ischemia after successful thrombolysis: a pro-
spective placebo-controlled angiographic study. Results of
the APRICOT Study. Circulation 1993, 87:1524-1530.
11. Veen G, Meyer A, Verheugt FW, Werter CJ, de Swart H, Lie KI, van
der Pol JM, Michels HR, van Eenige MJ: Culprit lesion morphology
and stenosis severity in the prediction of reocclusion after
coronary thrombolysis: angiographic results of the APRI-
COT study. Antithrombotics in the Prevention of Reocclu-
sion in Coronary Thrombolysis.  J Am Coll Cardiol 1993,
22:1755-1762.
12. Meijer A, Verheugt FW, van Eenige MJ, Werter CJ: Left ventricular
function at 3 months after successful thrombolysis. Impact
of reocclusion without reinfarction on ejection fraction,
regional function, and remodeling.  Circulation 1994,
90:1706-1714.
13. Nijland F, Kamp O, Verheugt FW, Veen G, Visser CA: Long-term
implications of reocclusion on left ventricular size and func-
tion after successful thrombolysis for first anterior myocar-
dial infarction. Circulation 1997, 95:111-117.
14. Comparison of invasive and conservative strategies after
treatment with intravenous tissue plasminogen activator in
acute myocardial infarction. Results of the thrombolysis in
myocardial infarction (TIMI) phase II trial. The TIMI Study
Group. N Engl J Med 1989, 320:618-627.
15. SWIFT trial of delayed elective intervention v conservative
treatment after thrombolysis with anistreplase in acute
myocardial infarction. SWIFT (Should We Intervene Fol-
lowing Thrombolysis?) Trial Study Group.  BMJ 1991,
302:555-560.
16. Erbel R, Pop T, Henrichs KJ, von Olshausen K, Schuster CJ, Rupprecht
HJ, Steuernagel C, Meyer J: Percutaneous transluminal coronaryCurrent Controlled Trials in Cardiovascular Medicine 2004, 5:11 http://cvm.controlled-trials.com/content/5/1/11
Page 7 of 8
(page number not for citation purposes)
angioplasty after thrombolytic therapy: a prospective con-
trolled randomized trial. J Am Coll Cardiol 1986, 8:485-495.
17. Guerci AD, Gerstenblith G, Brinker JA, Chandra NC, Gottlieb SO,
Bahr RD, Weiss JL, Shapiro EP, Flaherty JT, Bush DE, .: A rand-
omized trial of intravenous tissue plasminogen activator for
acute myocardial infarction with subsequent randomization
to elective coronary angioplasty.  N Engl J Med 1987,
317:1613-1618.
18. Rogers WJ, Baim DS, Gore JM, Brown BG, Roberts R, Williams DO,
Chesebro JH, Babb JD, Sheehan FH, Wackers FJ, .: Comparison of
immediate invasive, delayed invasive, and conservative
strategies after tissue-type plasminogen activator. Results of
the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A
trial. Circulation 1990, 81:1457-1476.
19. Simoons ML, Arnold AE, Betriu A, de Bono DP, Col J, Dougherty FC,
von Essen R, Lambertz H, Lubsen J, Meier B, .: Thrombolysis with
tissue plasminogen activator in acute myocardial infarction:
no additional benefit from immediate percutaneous coro-
nary angioplasty. Lancet 1988, 1:197-203.
20. Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Can-
dela RJ, Lee KL, Pitt B, Stack RS, O'Neill WW: A randomized trial
of immediate versus delayed elective angioplasty after intra-
venous tissue plasminogen activator in acute myocardial
infarction. N Engl J Med 1987, 317:581-588.
21. Froelicher VF, Perdue S, Pewen W, Risch M: Application of meta-
analysis using an electronic spread sheet to exercise testing
in patients after myocardial infarction.  Am J Med 1987,
83:1045-1054.
22. Basu S, Senior R, Raval U, Lahiri A: Superiority of nitrate-
enhanced 201Tl over conventional redistribution 201Tl
imaging for prognostic evaluation after myocardial infarc-
tion and thrombolysis [see comments].  Circulation 1997,
96:2932-2937.
23. Bigi R, Desideri A, Bax JJ, Galati A, Coletta C, Fiorentini C, Fioretti
PM:  Prognostic interaction between viability and residual
myocardial ischemia by dobutamine stress echocardiogra-
phy in patients with acute myocardial infarction and mildly
impaired left ventricular function. Am J Cardiol 2001, 87:283-288.
24. Huitink JM, Visser FC, Bax JJ, van Lingen A, Groenveld AB, Teule GJ,
Visser CA: Predictive value of planar 18F-fluorodeoxyglucose
imaging for cardiac events in patients after acute myocardial
infarction. Am J Cardiol 1998, 81:1072-1077.
25. Lee KS, Marwick TH, Cook SA, Go RT, Fix JS, James KB, Sapp SK,
MacIntyre WJ, Thomas JD: Prognosis of patients with left ven-
tricular dysfunction, with and without viable myocardium
after myocardial infarction. Relative efficacy of medical ther-
apy and revascularization. Circulation 1994, 90:2687-2694.
26. Marzullo POVIPWGNCMRIESC, CNR Institute of Clinical Physiology
PI:  Viability Impact on Prognosis (VIP): Results in 622
patients. J Am Coll Cardiol 1998, 31:167-167.
27. Nijland F, Kamp O, Verhorst PM, de Voogt WG, Visser CA: In-hos-
pital and long-term prognostic value of viable myocardium
detected by dobutamine echocardiography early after acute
myocardial infarction and its relation to indicators of left
ventricular systolic dysfunction. Am J Cardiol 2001, 88:949-955.
28. Petretta M, Cuocolo A, Bonaduce D, Nicolai E, Cardei S, Berardino
S, Ianniciello A, Apicella C, Bianchi V, Salvatore M: Incremental
prognostic value of thallium reinjection after stress- redistri-
bution imaging in patients with previous myocardial infarc-
tion and left ventricular dysfunction.  J Nucl Med 1997,
38:195-200.
29. Previtali M, Fetiveau R, Lanzarini L, Cavalotti C, Klersy C: Prognos-
tic value of myocardial viability and ischemia detected by
dobutamine stress echocardiography early after acute myo-
cardial infarction treated with thrombolysis. J Am Coll Cardiol
1998, 32:380-386.
30. Salustri A, Ciavatti M, Seccareccia F, Palamara A: Prediction of car-
diac events after uncomplicated acute myocardial infarction
by clinical variables and dobutamine stress test.  J Am Coll
Cardiol 1999, 34:435-440.
31. Sicari R, Picano E, Landi P, Pingitore A, Bigi R, Coletta C, Heyman J,
Casazza F, Previtali M, Mathias WJ, Dodi C, Minardi G, Lowenstein J,
Garyfallidis X, Cortigiani L, Morales MA, Raciti M: Prognostic value
of dobutamine-atropine stress echocardiography early after
acute myocardial infarction. Echo Dobutamine International
Cooperative (EDIC) Study. J Am Coll Cardiol 1997, 29:254-260.
32. Iskander S, Iskandrian AE: Prognostic utility of myocardial viabil-
ity assessment. Am J Cardiol 1999, 83:696-702, A7.
33. Carlos ME, Smart SC, Wynsen JC, Sagar KB: Dobutamine stress
echocardiography for risk stratification after myocardial inf-
arction [see comments]. Circulation 1997, 95:1402-1410.
34. Picano E, Sicari R, Landi P, Cortigiani L, Bigi R, Coletta C, Galati A,
Heyman J, Mattioli R, Previtali M, Mathias WJ, Dodi C, Minardi G,
Lowenstein J, Seveso G, Pingitore A, Salustri A, Raciti M: Prognostic
value of myocardial viability in medically treated patients
with global left ventricular dysfunction early after an acute
uncomplicated myocardial infarction: a dobutamine stress
echocardiographic study. Circulation 1998, 98:1078-1084.
35. Samad BA, Frick M, Hojer J, Urstad MJ: Early low-dose dob-
utamine echocardiography predicts late functional recovery
after thrombolyzed acute myocardial infarction. Am Heart J
1999, 137:489-493.
36. Yoshida K, Gould KL: Quantitative relation of myocardial inf-
arct size and myocardial viability by positron emission tom-
ography to left ventricular ejection fraction and 3-year
mortality with and without revascularization. J Am Coll Cardiol
1993, 22:984-997.
37. Nijland F, Kamp O, Verhorst PM, de Voogt WG, Bosch HG, Visser
CA: Myocardial viability: impact on left ventricular dilatation
after acute myocardial infarction. Heart 2002, 87:17-22.
38. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM: Accu-
racy of currently available techniques for prediction of func-
tional recovery after revascularization in patients with left
ventricular dysfunction due to chronic coronary artery dis-
ease: Comparison of pooled data. Journal of the American College
of Cardiology 1997, 30:1451-1460.
39. Platelet glycoprotein IIb/IIIa receptor blockade and low-
dose heparin during percutaneous coronary revasculariza-
tion. The EPILOG Investigators.  N Engl J Med 1997,
336:1689-1696.
40. Randomised placebo-controlled and balloon-angioplasty-
controlled trial to assess safety of coronary stenting with use
of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT
Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for
Stenting. Lancet 1998, 352:87-92.
41. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain
P, Boulenc JM, Morice MC, Maillard L, Pansieri M, Choussat R, Pinton
P:  Platelet glycoprotein IIb/IIIa inhibition with coronary
stenting for acute myocardial infarction. N Engl J Med 2001,
344:1895-1903.
42. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK,
Malmberg K, Rupprecht H, Zhao F, Chrolavicius S, Copland I, Fox KA:
Effects of pretreatment with clopidogrel and aspirin fol-
lowed by long-term therapy in patients undergoing percuta-
neous coronary intervention: the PCI-CURE study.  Lancet
2001, 358:527-533.
43. Steinhubl SR, Berger PB, Mann JTIII, Fry ET, DeLago A, Wilmer C,
Topol EJ: Early and sustained dual oral antiplatelet therapy
following percutaneous coronary intervention: a rand-
omized controlled trial. JAMA 2002, 288:2411-2420.
44. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR,
Knatterud G, Robertson TL, Terrin ML: Thrombolysis in Myocar-
dial-Infarction (Timi) Trial - Phase-I - Hemorrhagic Manifes-
tations and Changes in Plasma-Fibrinogen and the
Fibrinolytic System in Patients Treated with Recombinant
Tissue Plasminogen-Activator and Streptokinase. Journal of
the American College of Cardiology 1988, 11:1-11.
45. Poldermans D, Sozzi FB, Bax JJ, Boersma E, Duncker DJ, Vourvouri E,
Elhendy A, Valkema R, Roelandt JR: Influence of continuation of
beta blockers during dobutamine stress echocardiography
for the assessment of myocardial viability in patients with
severe ischemic left ventricular dysfunction. Am J Cardiol 2001,
88:68-70.
46. Weissman NJ, Levangie MW, Newell JB, Guerrero JL, Weyman AE,
Picard MH: Effect of beta-adrenergic receptor blockade on the
physiologic response to dobutamine stress
echocardiography. Am Heart J 1995, 130:248-253.
47. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigen-
baum H, Gutgesell H, Reichek N, Sahn D, Schnittger I, .: Recom-
mendations for quantitation of the left ventricle by two-
dimensional echocardiography. American Society of
Echocardiography Committee on Standards, SubcommitteePublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Current Controlled Trials in Cardiovascular Medicine 2004, 5:11 http://cvm.controlled-trials.com/content/5/1/11
Page 8 of 8
(page number not for citation purposes)
on Quantitation of Two-Dimensional Echocardiograms. J Am
Soc Echocardiogr 1989, 2:358-367.